Northeast Financial Consultants’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $563K | Sell |
1,073
-501
| -32% | -$263K | 0.02% | 195 |
|
|
2025
Q1 | $998K | Sell |
1,574
-94
| -6% | -$59.6K | 0.04% | 151 |
|
|
2024
Q4 | $1.19M | Hold |
1,668
| – | – | 0.05% | 141 |
|
|
2024
Q3 | $1.75M | Buy |
1,668
+3
| +0.2% | +$3.15K | 0.08% | 111 |
|
|
2024
Q2 | $1.75M | Hold |
1,665
| – | – | 0.08% | 106 |
|
|
2024
Q1 | $1.6M | Sell |
1,665
-66
| -4% | -$63.5K | 0.08% | 114 |
|
|
2023
Q4 | $1.52M | Hold |
1,731
| – | – | 0.08% | 114 |
|
|
2023
Q3 | $1.42M | Hold |
1,731
| – | – | 0.09% | 117 |
|
|
2023
Q2 | $1.24M | Hold |
1,731
| – | – | 0.08% | 123 |
|
|
2023
Q1 | $1.42M | Hold |
1,731
| – | – | 0.09% | 116 |
|
|
2022
Q4 | $1.25M | Sell |
1,731
-112
| -6% | -$80.8K | 0.08% | 123 |
|
|
2022
Q3 | $1.27M | Hold |
1,843
| – | – | 0.09% | 116 |
|
|
2022
Q2 | $1.09M | Sell |
1,843
-100
| -5% | -$59.1K | 0.08% | 132 |
|
|
2022
Q1 | $1.36M | Buy |
1,943
+100
| +5% | +$69.8K | 0.08% | 132 |
|
|
2021
Q4 | $1.16M | Hold |
1,843
| – | – | 0.07% | 145 |
|
|
2021
Q3 | $1.12M | Sell |
1,843
-40
| -2% | -$24.2K | 0.07% | 148 |
|
|
2021
Q2 | $1.05M | Hold |
1,883
| – | – | 0.07% | 153 |
|
|
2021
Q1 | $891K | Buy |
1,883
+540
| +40% | +$256K | 0.07% | 152 |
|
|
2020
Q4 | $649K | Sell |
1,343
-40
| -3% | -$19.3K | 0.05% | 167 |
|
|
2020
Q3 | $774K | Sell |
1,383
-134
| -9% | -$75K | 0.07% | 141 |
|
|
2020
Q2 | $945K | Buy |
1,517
+20
| +1% | +$12.5K | 0.09% | 129 |
|
|
2020
Q1 | $731K | Buy |
1,497
+310
| +26% | +$151K | 0.08% | 144 |
|
|
2019
Q4 | $446K | Sell |
1,187
-15
| -1% | -$5.64K | 0.04% | 192 |
|
|
2019
Q3 | $333K | Sell |
1,202
-15
| -1% | -$4.16K | 0.03% | 221 |
|
|
2019
Q2 | $381K | Buy |
1,217
+50
| +4% | +$15.7K | 0.04% | 202 |
|
|
2019
Q1 | $479K | Buy |
+1,167
| New | +$479K | 0.05% | 180 |
|